Drug details

Mektovi (binimetinib tablets)

type of Antineoplastics MEK Inhibitors

Mektovi (binimetinib) is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• nausea,
• loss of appetite,
• dark urine,
• vomiting,
• pale skin,
• shortness of breath,
• yellowing of the skin or eyes (jaundice),
• chest pain,
• dizziness,
• headache,
• weakness,
• cough,
• unexplained muscle pain,
• sudden cough,
• vision changes,
• bloody or tarry stools,
• coughing up blood,
• vomit that looks like coffee grounds,
• eye pain or swelling,
• seeing halos around lights,
• tenderness,
• severe skin rash,
• swelling in your feet or ankles
• seeing color “dots” in your vision,
• skin pain or swelling,
• redness and peeling skin on your hands or feet,
• pounding heartbeats, and
• pain or swelling in an arm or leg,
• cold feeling in an arm or leg,

The following drugs are related to Mektovi, either as a replacement or used together:

• Braftovi (encorafenib capsules)
• Cotellic (cobimetinib tablets)
• Tafinlar (dabrafenib capsules)
• Imlygic (talimogene laherparepvec suspension for intralesional injection)
• Yervoy (ipilimumab injection)
• Keytruda (pembrolizumab for injection)
• Kimmtrak (tebentafusp-tebn injection, for intravenous use)
• Mekinist (trametinib tablets)
• Opdualag (nivolumab and relatlimab-rmbw injection)
• Opdivo (nivolumab injection)
• Sylatron (peginterferon alfa-2b)
• Zelboraf (vemurafenib)